Description: Viridian Therapeutics, Inc., a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED. It also provides VRDN-006 a preclinical program for autoimmune disease. In addition, the company offers VRDN-006 and VRDN-008 a preclinical program for autoimmune disease. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021.Viridian Therapeutics, Inc. was founded in 2010 and is headquartered in Waltham, Massachusetts.
Home Page: www.viridiantherapeutics.com
221 Crescent Street
Waltham,
MA
02453
United States
Phone:
617 272 4600
Officers
| Name | Title |
|---|---|
| Mr. Stephen F. Mahoney J.D., MBA | CEO, President & Director |
| Mr. Seth Harmon | Senior VP of Finance and Accounting, Principal Financial & Accounting Officer |
| Mr. Thomas W. Beetham J.D., MBA | Chief Operating Officer |
| Dr. Eric N. Olson Ph.D. | Co-Founder & Chairman of Scientific Advisory Board |
| Dr. Michael R. Bristow M.D., Ph.D. | Co-Founder & Member of the Scientific Advisory Board |
| Dr. Marvin H. Caruthers Ph.D. | Co-Founder & Scientific Advisory Board Member |
| Mr. Vahe Bedian Ph.D. | Co-Founder & Scientific Advisor |
| Ms. Jennifer Tousignant J.D. | Chief Legal Officer |
| Mr. John A. Jordan | Vice President of Investor Relations & Corporate Communications |
| Ms. Melissa Manno | Chief Human Resources Officer |
Exchange: F
Country: DE : Germany
Currency: Euro (€)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 2.9264 |
| Price-to-Sales TTM: | 4898.0283 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 94 |